» Articles » PMID: 31109382

H3F3A-G34R Mutant High Grade Neuroepithelial Neoplasms with Glial and Dysplastic Ganglion Cell Components

Overview
Publisher Biomed Central
Specialty Neurology
Date 2019 May 22
PMID 31109382
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The recently described malignant neuro-epithelial tumors with histone H3F3A point mutations at G34 (NET-H3-G34) occur most often in cerebral hemispheres of teenagers and young adults, and have a generally adverse prognosis. These tumors have been histologically classified as glioblastoma or primitive neuroectodermal tumor (PNET) in the past, and have not been defined as a separate entity in the revised WHO classification of tumors of the CNS 2016. Here, we report two cases of NET-H3-G34 with glial and dysplastic ganglion cell components affecting teenagers. Patients were treated with surgery and radiochemotherapy with temozolomide. One patient underwent partial resection and deceased 21 months after diagnosis, while the other patient is alive without evidence of disease 15 months after total resection. So far, a dysplastic ganglion cell component has not been described in NET-H-G34, and its presence raises a possible relation to (anaplastic) gangliogliomas. Genome-wide copy number analysis did not provide unequivocal evidence that these tumors represent anaplastic variants of gangliogliomas, as opposed to NET-H3-G34. Our observations expand the morphologic spectrum of NET-H3-G34. Further cases of NET-H3-G34 with dysplastic ganglion cells should be clinically followed to find differences or similarities in their biological behavior, as compared to NET-H3-G34 and anaplastic gangliogliomas.

Citing Articles

Multimodal magnetic resonance imaging (MRI) of juvenile and adult diffuse hemispheric gliomas with H3 G34-mutation: a case description.

Hu W, Shao H, Yang X, Zheng L, Li S, Tan Q Quant Imaging Med Surg. 2024; 14(10):7740-7748.

PMID: 39429581 PMC: 11485332. DOI: 10.21037/qims-24-485.


Molecular and Pathological Features of Paediatric High-Grade Gliomas.

Blasco-Santana L, Colmenero I Int J Mol Sci. 2024; 25(15).

PMID: 39126064 PMC: 11312892. DOI: 10.3390/ijms25158498.


Pediatric CNS tumors and 2021 WHO classification: what do oncologists need from pathologists?.

dAmati A, Bargiacchi L, Rossi S, Carai A, Bertero L, Barresi V Front Mol Neurosci. 2024; 17:1268038.

PMID: 38544524 PMC: 10966132. DOI: 10.3389/fnmol.2024.1268038.


Midline invasion predicts poor prognosis in diffuse hemispheric glioma, H3 G34-mutant: an individual participant data review.

Kegoya Y, Otani Y, Inoue Y, Mizuta R, Higaki F, Washio K J Neurooncol. 2024; 167(1):201-210.

PMID: 38427132 PMC: 10978637. DOI: 10.1007/s11060-024-04587-5.


H3G34-Mutant Gliomas-A Review of Molecular Pathogenesis and Therapeutic Options.

Nguyen A, Soto J, Gonzalez S, Murillo J, Trumble E, Shan F Biomedicines. 2023; 11(7).

PMID: 37509641 PMC: 10377039. DOI: 10.3390/biomedicines11072002.


References
1.
Puntonet J, Dangouloff-Ros V, Saffroy R, Pages M, Andreiuolo F, Grill J . Historadiological correlations in high-grade glioma with the histone 3.3 G34R mutation. J Neuroradiol. 2018; 45(5):316-322. DOI: 10.1016/j.neurad.2018.02.006. View

2.
Bjerke L, Mackay A, Nandhabalan M, Burford A, Jury A, Popov S . Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov. 2013; 3(5):512-9. PMC: 3763966. DOI: 10.1158/2159-8290.CD-12-0426. View

3.
Zanello M, Pages M, Tauziede-Espariat A, Saffroy R, Puget S, Lacroix L . Clinical, Imaging, Histopathological and Molecular Characterization of Anaplastic Ganglioglioma. J Neuropathol Exp Neurol. 2016; 75(10):971-980. DOI: 10.1093/jnen/nlw074. View

4.
Grill J, Massimino M, Bouffet E, Azizi A, McCowage G, Canete A . Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma. J Clin Oncol. 2018; 36(10):951-958. DOI: 10.1200/JCO.2017.76.0611. View

5.
Kleinschmidt-DeMasters B, Donson A, Foreman N, Dorris K . H3 K27M Mutation in Gangliogliomas can be Associated with Poor Prognosis. Brain Pathol. 2017; 27(6):846-850. PMC: 8029072. DOI: 10.1111/bpa.12455. View